Acarbose - prevents MI and CV diseases

Currently, the important of monitoring of postprandial (aftermeal) sugar has been highlighted because more clinical studies have proven that postprandial hyperglycemia is harmful to any patient due to the metabolic disequilibrium.
(Monnier L,Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increatments to overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26: 881-5)

In a meta-analysis of seven randomized, double-blinded, placebo-controlled acarbose studies with a minimum of 52weeks treatment duration, it founds that, acarbose showed favorable trends towards risk reduction of all cardiovascular events (p=0.0061). A significant risk reduction for MI (p=0.021)

(Hanefeld M, Cagatay M, Petrowitsch T et al. Acarbose reduces the risk of myocardial infarction in type 2 diabetic patients: meta-analysis of seven long term studies. European Heart Journal 2004; 25: 10-6)

(This page is authored by Mai and is reproduced at http://gettoknowdrugs.blogspot.com)